Revenue
$37.00K
Fiscal year ended 2017-12-31Operating income
-$8.97M
Fiscal year ended 2017-12-31Free cash flow
-$8.50M
Fiscal year ended 2017-12-31BIO-PATH HOLDINGS, INC. (BPTH) reported revenue of $37.00K and net income of -$7.02M for the fiscal year ended 2017-12-31. This page shows 1 annual period of income statement, balance sheet and cash flow figures normalized from BIO-PATH HOLDINGS, INC.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Pharmaceutical Preparations.
Income
| Metric | 2017-12-31 |
|---|---|
| Revenue | $37.00K |
| Cost of revenue | Unavailable |
| Gross profit | Unavailable |
| Operating income | -$8.97M |
| Net income | -$7.02M |
| Research & development | $5.48M |
| Weighted-average diluted shares | Unavailable |
| Pretax income | Unavailable |
| Income tax expense | Unavailable |
| Diluted EPS | Unavailable |
| Selling, general & administrative | Unavailable |
| General & administrative | $3.52M |
| Selling & marketing | Unavailable |
Balance
| Metric | 2017-12-31 |
|---|---|
| Cash & equivalents | Unavailable |
| Total assets | $8.86M |
| Current assets | $7.44M |
| Total liabilities | $791.00K |
| Current liabilities | $791.00K |
| Total equity incl. NCI | $8.07M |
| Temporary (mezzanine) equity | Unavailable |
| Inventory | Unavailable |
| Accounts receivable | Unavailable |
| Goodwill | Unavailable |
| Long-term debt | Unavailable |
| Accounts payable | $52.00K |
Cash flow
| Metric | 2017-12-31 |
|---|---|
| Operating cash flow | -$7.96M |
| Capital expenditures | $538.00K |
| Investing cash flow | -$538.00K |
| Financing cash flow | Unavailable |
| Net change in cash | Unavailable |
| Stock-based compensation | $793.00K |
| Common dividends paid | Unavailable |
| Common share repurchases | Unavailable |
| Depreciation & amortization | Unavailable |
Derived
| Metric | 2017-12-31 |
|---|---|
| Free cash flow | -$8.50M |
| Gross margin | Unavailable |
| Operating margin | -24232.4% |
| FCF margin | -22959.5% |
| SBC / revenue | 2143.2% |
| Current ratio | 9.40x |
| Revenue YoY growth | 184.6% |
| Net margin | -18981.1% |
| R&D / revenue | 14810.8% |
| CapEx / revenue | 1454.1% |
| Long-term debt / equity | Unavailable |
| Effective tax rate | Unavailable |
Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open BPTH in the interactive workspace to inspect any figure back to its filing.
Source filings
10-Q · Filed 2026-05-20View SEC filing
10-Q · Filed 2026-01-13View SEC filing
10-Q · Filed 2025-08-14View SEC filing
10-Q · Filed 2025-05-15View SEC filing
10-K · Filed 2025-03-27View SEC filing
10-Q · Filed 2024-11-14View SEC filing
Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.